

Nice & Green provides funding of €20 million to Oryzon for executing clinical trials in oncology and CNS

Nyon, Switzerland, July 5th, 2022 – Nice & Green, the Swiss investment firm, provides financing of up to €20 million to Oryzon (ORY:SM), a Spanish clinical-stage biopharmaceutical company. Oryzon is the European leader in leveraging epigenetics to develop innovative therapeutics for patients with cancer and CNS disorders. With these additional funds from Nice & Green, Oryzon will extend its cash runway and continue its ongoing clinical trials in oncology and CNS.

The financing agreement signed between Nice & Green and Oryzon is materialized via a flexible Convertible Bonds program and extends over a period of 30 months. The funding scheme consists of four consecutive tranches as follows: one tranche of €8 million and three future optional tranches of €4 million to be withdrawn at the discretion of Oryzon.

Marc Cattelani, CEO of Nice & Green, stated: “We are thrilled to embark on this journey with Oryzon to help strengthen their equity capital and support the advancement of their clinical trials. As a responsible and loyal financial partner, Nice & Green will remain attentive to the evolving financing needs of Oryzon's management team in the near and long term”.

Dr. Carlos Buesa, CEO of Oryzon, said: "In an increasingly volatile and unpredictable market, we are excited to have secured this financial support from Nice & Green. This complementary funding allows us to further strengthen our balance sheet, extending substantially our cash runway and allowing us to laser focus on the execution of the ongoing clinical trials that shall provide substantial inflection points in the next quarters”.

This new partnership with Oryzon falls under Nice & Green’s commitment to facilitate listed companies’ access to flexible funding and enable them to achieve long-term growth.

About Nice & Green

Nice & Green is a privately held equity financing firm providing tailor-made and flexible financing solutions for listed Micro-, Small- and Mid-Cap companies in Europe. Nice & Green works towards improving financing solutions to better meet the evolving capital raising needs of listed companies. It strives to create value for both the companies and their shareholders, thanks to a virtuous approach for investment. Find out more at nicengreen.ch.

About Oryzon

Oryzon (ORY:SM) is a clinical stage biopharmaceutical company the European leader in the development of epigenetics-based therapeutics. Oryzon has one of the strongest portfolios in the field, with two LSD1 inhibitors, iadademstat and vafidemstat, in Phase II clinical trials, and other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. Find out more at oryzon.com.

Contact Information

Michèle Aouad
Head of Marketing and Communications

+41 22 361 36 97
maouad@nicengreen.ch